The World Health Organization and drugmaker Eli Lilly and Co. are warning patients to be wary of fake versions of weight-loss and diabetes medicines.
FILE - This photo combo provided by the FDA shows an authentic Ozempic needle, left and a counterfeit needle, right. The World Health Organization and drugmaker Eli Lilly and Co. are warning people to be wary of fake versions of popular weight-loss and diabetes medicines. The World Health Organization and drugmaker Eli Lilly and Co.
Lilly said any products marketed as tirzepatide and not Mounjaro or Zepbound were not made by the drugmaker and are not approved by the U.S. Food and Drug Administration.The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supplyDemand for the drugs Mounjaro and Zepbound has far outpaced supply over the last year, forcing Eli Lilly to invest heavily to scale up its manufacturing.
Read more »
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro.
Read more »
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro.
Read more »
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro. The drugmaker said Friday that it was more than doubling its investment in a site near its Indianapolis headquarters.
Read more »
Eli Lilly's big GLP-1 investment — plus, what we want from 4 portfolio stock earningsThe Investing Club holds its 'Morning Meeting' every weekday at 10:20 a.m. ET.
Read more »
Mounjaro And Zepbound Shortages Targeted With $5.3 Billion Eli Lilly InvestmentI cover breaking news for Forbes. Before Forbes, I worked as a reporter for USA Today in Asheville and Black Mountain, North Carolina. I received my bachelor's degree in journalism from Auburn University and my master's degree in journalism from Northwestern University.
Read more »